{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:55:04Z","timestamp":1774572904460,"version":"3.50.1"},"reference-count":24,"publisher":"CAIRN.INFO","issue":"HS1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:p>Introduction : En 2018, le D\u00e9partement de l\u2019Is\u00e8re a mis en place une campagne de promotion de la vaccination contre les papillomavirus humains (HPV) appel\u00e9e \u00ab StopHPV \u00bb . Notre article vise \u00e0 d\u00e9crire et \u00e9tudier la contribution de cette campagne sur l\u2019\u00e9volution de la couverture vaccinale HPV en Is\u00e8re. M\u00e9thode : Une approche longitudinale, avec une composante qualitative (focus groups) apportant du contexte aux r\u00e9sultats quantitatifs (enqu\u00eates dans diff\u00e9rents coll\u00e8ges du d\u00e9partement) associ\u00e9s aux donn\u00e9es de couverture vaccinale, a \u00e9t\u00e9 adopt\u00e9e pour cette recherche. R\u00e9sultats : En Is\u00e8re, la couverture vaccinale pour une dose de vaccin contre le HPV est pass\u00e9 de 21,7 % en 2017 \u00e0 49,7 % en 2022 (Sant\u00e9 Publique France). En 2022-2023, la principale raison de non-vaccination reste la crainte des effets secondaires du vaccin, suivie par le manque de temps. 95 % des participants aux enqu\u00eates consultent leur m\u00e9decin traitant pour obtenir des informations sur la vaccination. Une association significative a \u00e9t\u00e9 observ\u00e9e entre la cat\u00e9gorie socio-professionnelle des parents et le statut vaccinal des filles, ainsi qu\u2019entre le statut R\u00e9seaux d\u2019\u00c9ducation Prioritaire (REP) et la connaissance du vaccin contre les HPV. Conclusions : Notre \u00e9tude sugg\u00e8re une efficacit\u00e9 de la campagne StopHPV, dont l\u2019objectif de doubler la couverture vaccinale HPV d\u2019ici \u00e0 2022 a \u00e9t\u00e9 atteint. Notre \u00e9valuation souligne l\u2019importance de maintenir la formation des m\u00e9decins g\u00e9n\u00e9ralistes \u00e0 la vaccination HPV et la pertinence de r\u00e9aliser une campagne de vaccination dans les \u00e9tablissements scolaires. Il semble \u00e9galement essentiel de travailler sur les in\u00e9galit\u00e9s socio-culturelles en diffusant un message cibl\u00e9 dans les \u00e9tablissements class\u00e9s REP.<\/jats:p>","DOI":"10.3917\/spub.hs1.2025.0123","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:19:26Z","timestamp":1755181166000},"page":"123-154","source":"Crossref","is-referenced-by-count":0,"title":["Contribution de la campagne \u00ab StopHPV \u00bb sur la couverture vaccinale en Is\u00e8re : \u00e9valuation par m\u00e9thode mixte"],"prefix":"10.3917","volume":"vol. 37","author":[{"given":"Aur\u00e9lie","family":"Gauchet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Pillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Ailloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoann","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charl\u00e8ne","family":"Jelinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Vareilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2273","reference":[{"key":"rb1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0334-z"},{"key":"rb2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv086"},{"key":"rb3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030391"},{"key":"rb4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa621"},{"key":"rb5","unstructured":"5. Sant\u00e9 Publique France. Donn\u00e9es de couverture vaccinale papillomavirus humains (HPV) par groupe d\u2019\u00e2ge [en ligne]. [cit\u00e9 le 3 ao\u00fbt 2024]. Disponible sur : https:\/\/www.santepubliquefrance.fr\/determinants-de-sante\/vaccination\/articles\/donnees-de-couverture-vaccinale-papillomavirus-humains-hpv-par-groupe-d-age"},{"key":"rb6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.040"},{"key":"rb7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.041"},{"key":"rb8","unstructured":"8. IReSP, aviesan. La vaccination contre le papillomavirus en France. Etat des lieux des connaissances et des actions d\u2019am\u00e9lioration de la couverture vaccinale dans le cadre de l\u2019action 1.2.5 du Plan Cancer 2014-2019 [en ligne]. 2017 [cit\u00e9 le 3 ao\u00fbt 2024]. Disponible sur : https:\/\/www.iresp.net\/wp-content\/uploads\/2019\/02\/RAPPORT_V7_final-erratum-version-compr%C3%A9ss%C3%A9e.pdf"},{"key":"rb9","doi-asserted-by":"publisher","DOI":"10.1016\/0749-5978(91)90020-T"},{"key":"rb10","unstructured":"10. Pothrat L. Proposition d\u2019un programme de promotion de la vaccination contre les papillomavirus en Is\u00e8re 2018-2022 [th\u00e8se de m\u00e9decine]. Grenoble, France : Universit\u00e9 Grenoble Alpes ; 2019. 73 p. Disponible sur : https:\/\/dumas.ccsd.cnrs.fr\/UFR_MEDGRENOBLE\/dumas-02118676. Consult\u00e9 le 3 ao\u00fbt 2024."},{"key":"rb11","doi-asserted-by":"publisher","DOI":"10.1177\/109019817400200403"},{"key":"rb12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-0597.2007.00325.x"},{"key":"rb13","doi-asserted-by":"crossref","unstructured":"13. Feng Y, Feng, Ran, Liu Y. Social media promotion, risk perception, and parental support for adolescent girls\u2019 HPV vaccination : taking consideration of future consequences and sexual attitudes as moderators. Health Care for Women International. 2 avril 2024 ; 45(4) : 43043.","DOI":"10.1080\/07399332.2023.2190979"},{"key":"rb14","unstructured":"14. Shemelova E. Facteurs influen\u00e7ant la prise de d\u00e9cision sur la vaccination contre le HPV [th\u00e8se de psychologie clinique, pathologie]. Grenoble, France : Universit\u00e9 Grenoble Alpes ; 2016, 213 p. Disponible sur : https:\/\/theses.hal.science\/tel-01691595\/"},{"key":"rb15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2007.05.013"},{"key":"rb16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.06.018"},{"key":"rb17","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13778"},{"key":"rb18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057943"},{"key":"rb19","unstructured":"19. Thilly N, Michel M, Simon M, Bocquier A, Gagneux-Brunon A, Gauchet A, et al. Effectiveness of a school- and primary care-based HPV vaccination intervention in France : the PrevHPV cluster randomized trial. JAMA Netw Open. 2024 ; 7(5) : e2411938. doi : 10.1001\/jamanetworkopen.2024.11938."},{"key":"rb20","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2381300"},{"key":"rb21","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-023-01227-8"},{"key":"rb22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.072"},{"key":"rb23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1564436"},{"key":"rb24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.028"}],"container-title":["Sant\u00e9 Publique"],"original-title":[],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:06:07Z","timestamp":1774569967000},"score":1,"resource":{"primary":{"URL":"https:\/\/stm.cairn.info\/revue-sante-publique-2025-HS1-page-123?lang=fr&ref=doi"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":24,"journal-issue":{"issue":"HS1","published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.3917\/spub.hs1.2025.0123","relation":{},"ISSN":["0995-3914"],"issn-type":[{"value":"0995-3914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}